PHILADELPHIA and CHICAGO, Sept. 17, 2024 /PRNewswire/ — Richardson Sales Performance (Richardson), a leading global provider of sales training solutions, today announced its acquisition of Challenger, world-renowned for their research-based Challenger selling approach. This strategic acquisition unites two of the most influential names in the sales performance industry, creating an unparalleled powerhouse poised to deliver innovative, […]
Category Archives: Pr Newswire
Pr Newswire
Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024
16
Sep
Sep
Biologics License Application currently under review by U.S. FDA; PDUFA goal date of December 28, 2024 WALTHAM, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the presentation of longer-term data from its pivotal trial of cosibelimab, its anti-programmed death ligand-1 (“PD-L1”) […]
16
Sep
Sep
14 Deep TMS™ Devices Ordered by Large Mental Health Network BURLINGTON, Mass. and JERUSALEM, Sept. 16, 2024 (GLOBE NEWSWIRE) — BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the expansion of its Deep TMS™ platform along the East Coast […]
Pr Newswire
Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones
16
Sep
Sep
Initiated Phase IIb study of nature-derived psilocybin as a potential treatment for Adjustment Disorder in Palliative Care Expanded pipeline into Alcohol Use Disorder (AUD) and Substance Use Disorders (SUDs) through exclusive IP licensing agreement with Psylabs for its botanical psilocybin product Announced acquisition of synthetic psilocybin-based drug developer Clairvoyant, further bolstering AUD […]
16
Sep
Sep
Abstracts selected for 2 oral presentations and 2 poster presentations, including clinical and preclinical data sets WOODLAND HILLS, Calif., Sept. 16, 2024 (GLOBE NEWSWIRE) — Angitia Biopharmaceuticals, a global, clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for serious musculoskeletal diseases, today announced that data from its ongoing program evaluating AGA2118 […]
16
Sep
Sep
Dr. Beck’s extensive experience in CMC and product development will be instrumental as Abata enters clinical development this year WATERTOWN, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) — Abata Therapeutics, a clinical-stage biotech company focused on transforming lives with Treg therapies for severe autoimmune and inflammatory diseases, today announced the appointment of Joanne Beck, Ph.D., as […]
NANJING, China, Sept. 16, 2024 /PRNewswire/ — Vazyme (688105.SH), a leading life science technology company, significantly contributed to groundbreaking research published in Science Magazine through its innovative products. The study, which focuses on how mutant IDH1 inhibition activates tumor immunity by inducing double-stranded DNA (dsDNA) sensing, utilized Vazyme’s advanced tools to achieve compelling research results. […]
TAIPEI and BARCELONA, Spain, Sept. 16, 2024 /PRNewswire/ — A groundbreaking study conducted by PhytoHealth Corporation, a leading provider of botanical medicine, has revealed that combining Astragalus Polysaccharides (PG2®Lyo. Injection) with standard concurrent chemoradiotherapy (CCRT) significantly improves survival rates for patients with advanced esophageal cancer. The study enrolled 38 patients with stage IIb to IIIb esophageal […]
CAAS announces the conference call and webcast information for the Annual Meeting of Stockholders to be held on Tuesday, September 24, 2024 at 9:00 AM local time, or 9:00 PM EDT on Monday, September 23, 2024 WUHAN, China, Sept. 16, 2024 /PRNewswire/ — China Automotive Systems, Inc. (Nasdaq: CAAS) (“CAAS” or the “Company”), a leading power steering […]
In patients with non-small cell lung cancer (NSCLC) or melanoma who had acquired resistance to checkpoint inhibitors (CPIs), ATN-037 in combination with KEYTRUDA®(pembrolizumab) demonstrated an overall response rate (ORR) of 21.1% and a disease control rate (DCR) of 89.5%. Data from the Phase I dose escalation showed ATN-037’s potential in reversing resistance to anti-PD-1 therapies. […]